the university of toronto stepped deeper into the contest for connaught biosciences inc. by reaching an unusual agreement with ciba-geigy ltd. and chiron corp . the university said 0 the two companies agreed to spend 25 million canadian dollars -lrb- $ 21.3 million -rrb- over 10 years on research at canadian universities if they are successful in acquiring the vaccine maker . it said 0 $ 10 million would go to the university of toronto . ciba-geigy and chiron have made a joint bid of c$ 866 million for connaught , and institut merieux s.a. of france has made a rival bid of c$ 942 million . the university is seeking an injunction against the merieux bid , arguing that connaught 's predecessor company agreed in 1972 that connaught 's ownership would n't be transferred to foreigners . the university implied that it would drop its opposition to foreign ownership if ciba-geigy and chiron are successful with their lower bid . it said 0 the new agreement would `` replace '' the old one that forms the basis of its suit against the merieux takeover . `` notwithstanding foreign ownership of connaught , this accord would enhance research and development in canada , '' said james keffer , the university 's vice president of research . ciba-geigy is a swiss pharmaceutical company and chiron is based in emeryville , calif . in a statement , jacques-francois martin , director general of merieux , said 0 the french company is still determined to acquire connaught . while he did n't comment directly on the pact between ciba-geigy and the university , he said 0 merieux can transfer new products and technologies to connaught more rapidly than other companies `` not currently producing and marketing vaccines -lcb- who -rcb- can only promise this for some ... years in the future . '' in national over-the-counter trading yesterday , connaught closed at $ 28.625 , up $ 1.25 .